Korsana Biosciences (KRSA) Proxy filing summary

Executive summary

• Special meeting scheduled for November 13, 2026, online; shareholders will reconsider moving the legal domicile from Massachusetts to the Cayman Islands after the August 2026 vote failed to meet both required thresholds.

• The merger closed September 8, 2026; the redomestication is separate and will proceed only if both core proposals pass and required filings are completed.

• If completed, the same legal entity, business, management, assets, liabilities, Nasdaq listing and KRSA ticker continue; common shares convert one-for-one, with no exchange action required.

• Board cites potential reduction in shareholder litigation and greater protection for directors and officers, plus flexibility and predictability in corporate transactions; benefits are not assured.

Voting matters and shareholder proposals

• Proposal 1 seeks Massachusetts-law domestication approval; requires at least two-thirds of all shares entitled to vote. Abstentions, broker non-votes and failures to vote count against it.

• Proposal 2 seeks Cayman continuation and adoption of the Cayman Articles; requires at least two-thirds of votes properly cast. Abstentions and broker non-votes have no effect.

• Proposal 3 seeks authority to adjourn if needed to solicit more proxies; approval requires affirmative votes to exceed opposing votes. The Board unanimously recommends FOR all three proposals.

• At the August 26, 2026 annual meeting, support was ~61.8% of votes cast but ~44.8% of outstanding shares; the proposal failed both required thresholds.

• A majority of outstanding voting shares constitutes a quorum; uninstructed street-name shares are not expected to count toward quorum, making participation especially consequential for Proposal 1.

Board of directors and corporate governance

• Cayman Articles would replace annual director elections with three staggered classes serving three-year terms; elections by shareholders use plurality voting.

• While at least 30% of originally issued Series B preferred shares remain outstanding, holders elect four directors; each preferred director has three board votes.

• Board size would be set by the Board; vacancies generally filled by directors, and directors may be removed only for cause, subject to preferred-share rights.

• Cayman Articles provide advance-notice rules for shareholder nominations and business; qualifying holders of at least 40% of paid-up voting share capital may requisition a general meeting.